Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.

Also called NCT04206228

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 149 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04206228
Other papers using this trial's data
  • Intravenous iron supplement for iron deficiency in patients with severe aortic stenosis scheduled for transcatheter aortic valve implantation: results of the IIISAS randomised trial European journal of heart failure, 2022-07 DOI, PubMed 35579454, PMC9544901 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Norway (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04206228. Randomized; triple masking; primary purpose treatment. Start 2020-01-13 (actual); primary completion 2022-02-15 (actual). Results posted on 2026-04-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis
Acronym
IIISAS
Condition
Severe Aortic Stenosis
Condition
Iron-deficiency
Intervention (Drug)
Intravenous iron isomaltoside
Intervention (Drug)
Placebo
Lead sponsor
Oslo University Hospital (class: other)

Record details

Record id
cardio:ct-nct04206228
Content hash
09cd80e6f1b42ef0929f2ca9735a9457786daba286a41576278d0dd610643e51